EVC as a Radioligand Therapy Target
EVC, EvC ciliary complex subunit 1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, EVC staining is highest in endometrial cancer (100% of samples positive), colorectal cancer (100% of samples positive) and head and neck cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is EVC a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in endometrial cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EVC expression in cancer
Protein expression of EVC across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Endometrial Cancer | 0.69 | High | 100% |
| Colorectal Cancer | 0.67 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Neuroendocrine Tumors | 0.67 | High | 100% |
| Glioma | 0.67 | High | 100% |
| Kidney Cancer | 0.61 | High | 100% |
| Cervical Cancer | 0.61 | High | 100% |
| Melanoma | 0.60 | High | 100% |
| Lung Cancer | 0.59 | High | 100% |
| Pancreatic Cancer | 0.57 | High | 90% |
| Skin Cancer | 0.56 | High | 100% |
| Breast Cancer | 0.53 | High | 92% |
| Gastric Cancer | 0.48 | Medium | 89% |
| Ovarian Cancer | 0.47 | Medium | 83% |
| Bladder Cancer | 0.46 | Medium | 91% |
| Liver Cancer | 0.44 | Medium | 75% |
| Prostate Cancer | 0.28 | Medium | 58% |
| Testicular Cancer | 0.27 | Medium | 50% |
| Lymphoma | 0.22 | Medium | 58% |
Is EVC internalized?
Nuclens has not yet extracted internalization evidence for EVC. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
EVC clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for EVC yet. Search ClinicalTrials.gov for EVC trials.
EVC normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EVC in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EVC gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: 0.09 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related endometrial cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · B7-H3 (CD276) · SSTR2 · ITGAV · STEAP2
See all radioligand therapy targets in endometrial cancer.
See how EVC ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.